Literature DB >> 18838309

Early referral to cystic fibrosis specialist centre impacts on respiratory outcome.

P Lebecque1, A Leonard, K De Boeck, F De Baets, A Malfroot, G Casimir, K Desager, V Godding, T Leal.   

Abstract

BACKGROUND: Published studies concerning the impact of specialist care on lung disease in cystic fibrosis remain limited and most are either biased due to comparison with historical controls and/or underpowered.
METHODS: In this retrospective multicentric study, data from all CF children fulfilling the following criteria were collected: 1) Age 6-<18 at the end of 2003; 2) diagnosis before 8 y; 3) follow-up in an accredited CF Belgian centre; 4) at least 1 spirometry and respiratory culture available for 2003. Group A included children referred > or =2 years after the diagnosis. Patients from Group A were then matched with a single early referred patient on the basis of 2 criteria: same centre, as closest age as possible (Group B).
RESULTS: Data from 217 children were collected (Group A: 67/217). Late referred patients had a lower FEV(1) (77.2%+/-22.4 vs 86.7% pred.+/-19.4, p=0.01) and a higher prevalence of Pseudomonas aeruginosa (38.6 vs 17.5%, p<0.05).
CONCLUSION: In this population of CF children, a delay of 6.1 y (vs 0.1 y) between diagnosis and referral to a specialist clinic resulted in poorer respiratory outcome at age 13.

Entities:  

Mesh:

Year:  2008        PMID: 18838309     DOI: 10.1016/j.jcf.2008.07.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  9 in total

1.  Increased adherence to CFF practice guidelines for pulmonary medications correlates with improved FEV1.

Authors:  Brooke M Moore; Theresa A Laguna; Meixia Liu; John J McNamara
Journal:  Pediatr Pulmonol       Date:  2012-09-19

2.  Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California.

Authors:  MyMy C Buu; Lee M Sanders; Jonathan A Mayo; Carlos E Milla; Paul H Wise
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

3.  Satisfaction and Concerns with Telemedicine Endocrine Care of Patients with Cystic Fibrosis.

Authors:  Rahat Ahmed; Margaret Greenfield; Christopher P Morley; Marisa Desimone
Journal:  Telemed Rep       Date:  2022-03-21

Review 4.  Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research?

Authors:  Beth K Potter; Sara D Khangura; Kylie Tingley; Pranesh Chakraborty; Julian Little
Journal:  Genet Med       Date:  2015-04-09       Impact factor: 8.822

5.  Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study.

Authors:  Helen L Barr; John Britton; Alan R Smyth; Andrew W Fogarty
Journal:  BMJ       Date:  2011-08-23

6.  Do children with cystic fibrosis receiving outreach care have poorer clinical outcomes than those treated at a specialist cystic fibrosis centre?

Authors:  Heinrich C Weber; Philip F Robinson; Nicole Saxby; Sean A Beggs; Ingrid Els; Rodney I Ehrlich
Journal:  Aust J Rural Health       Date:  2016-11-17       Impact factor: 1.662

7.  Patient and family perceptions of telehealth as part of the cystic fibrosis care model during COVID-19.

Authors:  Davis Jaclyn; NeSmith Andrew; Perkins Ryan; Bailey Julianna; Siracusa Christopher; Chaudary Nauman; M Powers; Sawicki Gregory S; Solomon George M
Journal:  J Cyst Fibros       Date:  2021-03-26       Impact factor: 5.527

8.  Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic.

Authors:  George M Solomon; Julianna Bailey; James Lawlor; Peter Scalia; Gregory S Sawicki; Christopher Dowd; Kathryn A Sabadosa; Aricca Van Citters
Journal:  J Cyst Fibros       Date:  2021-12       Impact factor: 5.482

9.  Disease-specific clinical trials networks: the example of cystic fibrosis.

Authors:  Kris De Boeck; Veerle Bulteel; Isabelle Fajac
Journal:  Eur J Pediatr       Date:  2016-03-15       Impact factor: 3.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.